Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes

Vakkat Muraleedharan1,2, Hazel Marsh1, Dheeraj Kapoor1, Kevin S Channer3,4 and T Hugh Jones1,2

1Robert Hague Centre for Diabetes and Endocrinology, Barnsley Hospital NHSFT, Gawber Road, Barnsley S75 2EP, UK, 2Department of Human Metabolism, The University of Sheffield, Beech Hill Road, Sheffield, UK, 3Department of Cardiology, Sheffield Teaching Hospital NHSFT, Royal Hallamshire Hospital, Sheffield, UK and 4Department of Cardiovascular Medicine, Sheffield Hallam University, City Campus, Howard Street, Sheffield S1 1WB, UK

(Correspondence should be addressed to V Muraleedharan who is now at King’s Mill Hospital, Sutton on Ashfield, Nottinghamshire NG17 4JL, UK; Email: v.muraleedharan@nhs.net; T H Jones; Email: hugh.jones@nhs.net)

Abstract

Objective: Men with type 2 diabetes are known to have a high prevalence of testosterone deficiency. No long-term data are available regarding testosterone and mortality in men with type 2 diabetes or any effect of testosterone replacement therapy (TRT). We report a 6-year follow-up study to examine the effect of baseline testosterone and TRT on all-cause mortality in men with type 2 diabetes and low testosterone.

Research design and methods: A total of 581 men with type 2 diabetes who had testosterone levels performed between 2002 and 2005 were followed up for a mean period of 5.8 ± 1.3 S.D. years. Mortality rates were compared between total testosterone > 10.4 nmol/l (300 ng/dl; n = 343) and testosterone ≤ 10.4 nmol/l (n = 238). The effect of TRT (as per normal clinical practise: 85.9% testosterone gel and 14.1% intramuscular testosterone undecanoate) was assessed retrospectively within the low testosterone group.

Results: Mortality was increased in the low testosterone group (17.2%) compared with the normal testosterone group (9%; P = 0.003) when controlled for covariates. In the Cox regression model, multivariate-adjusted hazard ratio (HR) for decreased survival was 2.02 (95% CI 1.2–3.4). TRT (mean duration 41.6 ± 20.7 months; n = 64) was associated with a reduced mortality of 8.4% compared with 19.2% (P = 0.002) in the untreated group (n = 174). The multivariate-adjusted HR for decreased survival in the untreated group was 2.3 (95% CI 1.3–3.9, P = 0.004).

Conclusions: Low testosterone levels predict an increase in all-cause mortality during long-term follow-up. Testosterone replacement may improve survival in hypogonadal men with type 2 diabetes.

Introduction

Several longitudinal population studies have reported that a low testosterone at baseline is associated with an increase in all-cause mortality (1). Some individual studies have specifically identified increases in cardiovascular, respiratory and cancer deaths (2, 3, 4). A meta-analysis of published research papers with a mean follow-up period of 9.7 years confirmed that low testosterone was associated with increased risk of all-cause and cardiovascular mortality in community based studies (1). Men with specific co-morbidities such as proven coronary artery disease and renal failure have also found that low testosterone predicts an increased risk of earlier death than those with the same condition and are testosterone replete (5, 6).

There is a high prevalence of low serum testosterone levels and clinical hypogonadism in men with type 2 diabetes (7, 8, 9). Importantly, it has been established that both free testosterone (FT) assayed by equilibrium dialysis and bioavailable testosterone (free plus albumin-bound) assayed by ammonium sulphate precipitation are low in men with type 2 diabetes (8, 10, 11). These findings demonstrate that low total testosterone (TT) cannot be fully accounted for by lower sex hormone binding globulin (SHBG) levels. Our previous study found a high prevalence of symptomatic hypogonadism in men with type 2 diabetes: 17% had TT < 8 nmol/l whereas a further 25% had testosterone levels between 8 and 12 nmol/l (8). Testosterone deficiency is known to have an adverse effect on several key cardiovascular risk factors which include central obesity, insulin resistance, hyperglycaemia, dyslipidaemia, inflammation and hypertension (12).

The major cause of death in men with type 2 diabetes is cardiovascular disease (CVD). Low testosterone has in
several studies have been linked with CVD (12). There is also evidence which has shown that the degree of atherosclerosis as assessed by the degree of carotid intimal media thickness (CIMT) is inversely associated with testosterone levels (13, 14, 15). One study found that a low testosterone status was associated with greater progression of atherosclerosis as assessed by CIMT over a 4-year follow-up period (14). Furthermore, low testosterone is associated with a pro-inflammatory milieu and testosterone replacement suppresses circulating cytokines (16, 17).

Interventional trials have reported that testosterone replacement improves insulin resistance, glycaemic control, visceral obesity and lipid profile in the short term (18, 19, 20, 21, 22, 23). A large multi-centre, randomised, double-blind, placebo-controlled study was recently undertaken in eight European countries, the TIMES2 study, which showed that testosterone replacement therapy (TRT) improves certain cardiovascular risk factors which included insulin resistance, cholesterol, lipoprotein(a), body fat composition and sexual function in men with type 2 diabetes and/or hypogonadism. Furthermore, it is not known if testosterone replacement has any effect on the longevity in these patients. We report a 6-year follow-up study of men with type 2 diabetes, looking at the impact of hypogonadism on mortality and the effect of testosterone replacement.

Subjects and methods

This was a prospective follow-up, using a cohort from a previously reported study on the prevalence of hypogonadism (8). The subjects involved in this study had been recruited from the district-wide diabetic retinopathy screening clinic, as well as the hospital diabetic clinic, and provided a representative sample from the general community. In addition, in this we also included all men with type 2 diabetes identified from the hospital database who had testosterone levels measured between October 2002 and December 2005 (during the same time period the original research cohort was recruited). All of these subjects were assessed and managed routinely within our diabetes clinic. The effect of TRT on mortality was based on a retrospective analysis of those subjects with hypogonadism who had been treated as part of normal clinical management compared with those who had not received treatment for reasons explained below. The study was approved by the South Yorkshire Research Ethics Committee.

Subjects were allocated to two groups based on the Endocrine Society Guidelines’ (24) recommended cut-off level: i) TT levels \( \leq 10.4 \text{ nmol/l} \) and ii) TT \( > 10.4 \text{ nmol/l} \). There were two different assays used for analysis of baseline TT. For those subjects from the hospital database, the assay was performed using a competitive chemiluminescent assay (Bayer Advia Centaur, Siemens Medical Solutions Diagnostics, Camberley, UK) and for those from the research database, a solid phase enzyme immunoassay (DRG Instruments GmbH, Marburg, Germany) was used. Both assays are validated methods for assessing TT. A total of 36 patients from the research cohort had a repeat testosterone assay performed using the competitive chemiluminescent assay within a few months of the original screening. The results were comparable by the two methods with the difference between the means of the two groups not being statistically different (0.33 nmol/l (95% CI –1.22 to 1.88; \( P=0.669) \)). All blood samples were taken between 0800 and 1100 h. SHBG was measured by solid phase enzyme immunoassay (DRG Instruments GmbH) for the research patients and by solid phase two-site chemiluminescent enzyme immunometric assay (Siemens Immulite, Siemens Medical Solutions Diagnostics) for the hospital clinic patients.

The effect of TRT on mortality was assessed retrospectively by including data from men who had received TRT for > 1 year. Mean duration of TRT was 41.6 ± 20.7 months. A total of 60 patients received TRT for > 12 months, 51 of these having treatment > 2 years. All the patients who received TRT were initiated and monitored within our routine clinics in the diabetes and endocrinology department. Subjects from the original research cohort who had a low testosterone were invited to attend our clinic for further assessment as part of good clinical practise. For all patients who were already under our clinical care, as well as those who attended after invitation, were further assessed clinically for symptoms, repeat testosterone and gonadotropins measurement and other appropriate investigations. Patients were offered TRT if it was clinically indicated. The reasons for subjects not receiving TRT included patient choice, declined to attend for further clinical assessment, no response to clinic invitation, declined treatment after further analysis between 2002 and 2005. Generally, TRT was mainly given to men with testosterone levels below the local laboratory normal assay range (<8.4 nmol/l), without a concomitant diagnosis of prostate cancer or other contra-indications to TRT.

The majority of subjects who received TRT was initiated on a testosterone gel preparation (60/64), while three had buccal testosterone tablets and one intramuscular depot testosterone undecanoate (Nebido). The choice of initial therapy was based on the combined decision between the patient and doctor. Doses were adjusted to achieve testosterone levels within the mid to upper normal range. As a result of patient choice and/or side effects, preparations were changed in some individuals. In the TRT group, 55 patients (85.9%) were stabilised on testosterone gel (1% testosterone gel Testogel/AndroGel or 2% testosterone gel via a metered pump; Tostran/Fortigel) and
nine patients (14.1%) on intramuscular testosterone undecanoate during the last 6 months or more of the study period.

The mean peak level achieved during the study period was 22.8 (± 9.9) nmol/l; 43 (67%) of the patients achieved a level of > 18 nmol/l. Patient compliance was good as evidenced by the progressive improvement in the testosterone levels in most of the patients during the follow-up visits.

The causes of death were obtained from hospital records when available. For the remaining patients, death certificates were obtained from the local and national registries. Acute illness is known to cause a decrease in testosterone levels, so deaths which occurred in the first 6 months after baseline assessment were excluded.

Baseline data on age, height, weight, BMI, smoking, glycaemic control (HbA1c), angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker use (ARB), HMG CoA reductase inhibitor use (statins) and pre-existing CVDs for most of the patients were available from the research database. The remaining data were obtained from the hospital records. The baseline factors were then analysed for significance between two groups. These factors were then included in the covariate analysis using the Cox regression model.

SHBG results were available for 436 patients. Bioavailable testosterone (BT) and FT were calculated using validated mathematical formulae, the Morris–Malkin and Vermeulen equations respectively (25, 26). After excluding deaths which occurred in the first 6 months (n = 4), data were then analysed using SPSS 15 Software with support from a University of Sheffield statistician. Kaplan–Meir curves were compared and significance was tested using the log rank method. Cox statistician. Kaplan–Meir curves were compared and significance was tested using the log rank method. Cox regression model in SPSS.

Baseline characteristics

A total of 591 patients with type 2 diabetes who had testosterone levels performed between the years 2002 and 2005 were identified from the databases. Baseline data is presented in Table 1. We excluded deaths occurring in the first 6 months (n = 4) and those patients with a normal testosterone level at screening but subsequently developed hypogonadism and received treatment (n = 6). The remaining 581 subjects were followed up for a mean period of 5.8 ± 1.7 years. Mean age was 59.5 years (± 10.8; range 31–88 years). A total of 238 (40.96%) had low TT (≤10.4 nmol/l) and 343 (59.03%) with TT > 10.4 nmol/l.

There were 353 patients from the research cohort and 228 patients from the hospital database who met the inclusion criteria and were included in the final analysis. The comparison between the two groups is shown in Table 2. The hospital database patients were older, more likely to have pre-existing CVD and statin treatment. The research cohort had more current smokers. There were no differences in weight, height, BMI, glycaemic control, ACE/ARB therapy, TT and SHBG levels between the groups.

The mean TT level was 15.7 ± 4.5 nmol/l in the normal testosterone group as compared with 7.5 ± 2.1 nmol/l in the low testosterone group (P ≤ 0.001). The weight (102.1 ± 31.4 (low testosterone) vs 95.2 ± 18.5 kg (normal testosterone), P < 0.001) and BMI (33.6 ± 6.1 vs 31.2 ± 5.3 kg/m²,

Table 1 Baseline characteristics.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Whole population</th>
<th>Patients with missing values*</th>
<th>Normal testosterone group</th>
<th>Low testosterone group</th>
<th>Significance (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>581</td>
<td>343</td>
<td>238</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testosterone levels (nmol/l)</td>
<td>12.4 (5.5)</td>
<td>0</td>
<td>15.7 (4.5)</td>
<td>7.5 (2)</td>
<td>&lt;0.001&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Age (years)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>59.5 (10.8)</td>
<td>0</td>
<td>58.9 (10.4)</td>
<td>60.3 (11.5)</td>
<td>0.15&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>SHBG levels (nmol/l)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>32.2 (19.7)</td>
<td>144 (24.8)</td>
<td>36.7 (20.8)</td>
<td>25.8 (16.2)</td>
<td>&lt;0.001&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HbA1c&lt;sup&gt;c&lt;/sup&gt;</td>
<td>7.3 (1.4)</td>
<td>8 (1.4%)</td>
<td>7.2 (1.4)</td>
<td>7.5 (1.3)</td>
<td>0.002&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Weight (kg)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>98 (20)</td>
<td>63 (10.8%)</td>
<td>95.2 (18.5)</td>
<td>102.1 (21.4)</td>
<td>&lt;0.001&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Height (cm)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>174.3 (6.8)</td>
<td>74 (12.7%)</td>
<td>174.3 (6.8)</td>
<td>174.3 (6.8)</td>
<td>0.94&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>BMI&lt;sup&gt;c&lt;/sup&gt;</td>
<td>32.4 (5.8)</td>
<td>89 (15.3%)</td>
<td>31.3 (5.3)</td>
<td>33.6 (6.1)</td>
<td>&lt;0.001&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Statin therapy&lt;sup&gt;b&lt;/sup&gt;</td>
<td>260 (48.1%)</td>
<td>40 (6.9%)</td>
<td>161 (60%)</td>
<td>99 (45%)</td>
<td>0.29&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Current smokers&lt;sup&gt;d&lt;/sup&gt;</td>
<td>104 (9.3%)</td>
<td>43 (7.4%)</td>
<td>67 (20.9%)</td>
<td>37 (17%)</td>
<td>0.089&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>ACEI/ARB therapy&lt;sup&gt;b&lt;/sup&gt;</td>
<td>260 (48.1%)</td>
<td>30 (5.2%)</td>
<td>183 (56%)</td>
<td>125 (55.8%)</td>
<td>1&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pre-existing CVD&lt;sup&gt;d&lt;/sup&gt;</td>
<td>213 (39.2%)</td>
<td>38 (6.5%)</td>
<td>120 (37.2%)</td>
<td>93 (42.3%)</td>
<td>0.25&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup>Mean with s.d.; <sup>b</sup>number with percentage within the groups; <sup>c</sup>numbers of patients with percentage of the total; <sup>d</sup>analysis by t-test; <sup>e</sup>by χ².

www.eje-online.org
Table 2 Comparison between Hospital and Research Cohorts.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hospital patients</th>
<th>Research patients</th>
<th>Significance (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>228</td>
<td>353</td>
<td></td>
</tr>
<tr>
<td>Testosterone levels (nmol/l)</td>
<td>11.9 ± 5.3</td>
<td>12.7 ± 5.6</td>
<td>0.079 (^c)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 ± 11.3</td>
<td>58 ± 10.2</td>
<td>&lt;0.001 (^c)</td>
</tr>
<tr>
<td>SHBG levels (nmol/l)</td>
<td>31.2 ± 18.9</td>
<td>32.4 ± 20</td>
<td>0.584 (^c)</td>
</tr>
<tr>
<td>HbA1c (^c)</td>
<td>7.4 ± 1.5</td>
<td>7.2 ± 1.3</td>
<td>0.096 (^c)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>97.1 ± 19.8</td>
<td>98.4 ± 20.1</td>
<td>0.482 (^c)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>174.7 ± 6.8</td>
<td>174.1 ± 6.7</td>
<td>0.356 (^c)</td>
</tr>
<tr>
<td>BMI (^c)</td>
<td>31.7 ± 5.5</td>
<td>32.4 ± 5.9</td>
<td>0.243 (^c)</td>
</tr>
<tr>
<td>Statin therapy (^b)</td>
<td>112 (59.3%)</td>
<td>169 (47.9%)</td>
<td>0.012 (^d)</td>
</tr>
<tr>
<td>Current smokers (^b)</td>
<td>35 (18.8%)</td>
<td>69 (19.5%)</td>
<td>0.017 (^d)</td>
</tr>
<tr>
<td>ACEI/ARB therapy (^b)</td>
<td>112 (56.6%)</td>
<td>196 (55.5%)</td>
<td>0.585 (^d)</td>
</tr>
<tr>
<td>Pre-existing CVD (^b)</td>
<td>97 (49.7%)</td>
<td>117 (33.3%)</td>
<td>&lt;0.001 (^d)</td>
</tr>
</tbody>
</table>

\(^a\)Mean with s.d.; \(^b\)number with percentage within the groups; \(^c\)analysis by t-test; \(^d\)by \(\chi^2\).

\(P<0.001\) were higher in the low testosterone group and they were more likely to have poorer diabetes control than the normal testosterone group (HbA1c, 7.5 ± 1.3 vs 7.2 ± 1.4; \(P=0.002\)). Both groups were matched for age, smoking status, pre-existing CVD, statin and ACE inhibitors or ARB therapy.

Mortality

There were 72 deaths after the initial 6-month period. Individual causes of deaths were 34 cardiovascular deaths (which included coronary artery disease, cerebrovascular disease, peripheral vascular disease and pulmonary embolism), 13 respiratory disease deaths, 17 cancer deaths and eight other causes which included gastrointestinal haemorrhage (3), renal failure (1), sepsis (3) and suicide (1). Mean baseline testosterone levels were significantly low in patients who died (10.9 ± 5.2 s.d.) when compared with those who are alive (12.6 ± 5.5; \(P=0.018\)). The mortality rate was 17.2% (41/238) in the low testosterone group compared with 9% (31/343; \(P=0.003\)) in the normal testosterone group.

The Kaplan–Meier survival curves showed a significant decrease in survival in the low testosterone group compared with the normal testosterone group (\(P=0.002\) log rank). In the Cox regression model (forward conditional) after adjusting for covariates (age, pre-existing CVD, weight, height, BMI, HbA1c, smoking, statin and ARB/ACEI therapy) at baseline, the HR for decreased survival was 2.02 (\(P=0.009\), 95% CI 1.2–3.4; Fig. 1).

The survival curves demonstrated evidence of divergence after 12 months of follow-up. Apart from testosterone other factors which significantly affected survival were age (HR 1.07; 95% CI 1.05–1.11; \(P<0.001\)), pre-existing CVD (2.1; 95% CI 1.2–3.6; \(P=0.008\)) and HbA1c (1.3; 95% CI 1.1–1.4; \(P=0.008\)). There were 17 cardiovascular deaths in each group. There were no significant differences between the two groups in cardiovascular and cancer mortality. However, at a sub-analysis using a TT cut-off level below the normal assay range of 8.4 nmol/l, there was a significant increase in cardiovascular mortality in low testosterone patients when compared with those above 8.4 nmol/l with a multivariate-adjusted HR 2.5 (\(P=0.021\), 95% CI 1.2–5.38).

The higher mortality persisted after adjusting for SHBG (HR 2.2; 95% CI 1.2–4; \(P=0.008\)). However, when age adjustment was performed along with SHBG, the significance in mortality was lost but approached significance (\(P=0.064\)). These results suggest an influence of age-related SHBG change on the mortality outcome. SHBG was not measured at baseline in all patients (437/581). When the hospital and research cohorts were analysed separately, the mortality difference persisted in the hospital cohort. However, there was a non-significant difference in the research cohort possibly due to a relatively small number of events in that group.

Further analysis using BT with a cut-off level of \(\leq 2.6\) nmol/l (below the normal range) demonstrated survival curves similar to those found with TT (2.4; 95% CI 1.3–4.6; \(P=0.006\); Fig. 2). However, there was no significant difference in mortality found with FT \(<225\) pmol/l with those above this cut-off level (\(P=0.19\)).

\*The number of patients alive at the start of the study and at the end of the study.

www.eje-online.org
Interestingly, in this analysis the difference in mortality persisted after adjustment for SHBG along with age. This may be due to the change in SHBG with TRT which might have an effect on long-term survival. However, as we do not have the data for SHBG after TRT this cannot be verified.

Discussion

This longitudinal cohort study is the first study in men with type 2 diabetes which demonstrates that testosterone status at baseline predicts a significant increase in risk of subsequent mortality in men with type 2 diabetes during long-term follow-up. Importantly, the increase in mortality was found to be independent of age, glycaemic control, BMI, pre-existing CVD, current smoking status and treatment with either statins, ACEI or ARB at baseline. Other factors which predicted increased mortality in this analysis were age, baseline HbA1c and pre-existing CVD. HbA1c and BMI were significantly higher in the low testosterone group. The major single cause of mortality in the study was CVD with acute coronary artery disease accounting for the majority of cases. No significant increase in CV mortality in the low testosterone group was identified. However, a sub-analysis of men with TT less than the normal range did detect an increased risk of CV mortality compared with those with levels within the normal range. There was also a trend towards an increase respiratory disease mortality in the low testosterone group, but the significance was lost when adjusted for covariates. This might be explained by the relatively small number of respiratory-related deaths in the cohort.

Although several population studies have reported an association of increased mortality with low testosterone, the effect of TRT has not been studied. When we reviewed those patients who received TRT for 1 year or longer, we found a beneficial effect improving survival in

Table 3 Baseline data for the treated and untreated groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Untreated</th>
<th>Treated</th>
<th>Patients with missing values</th>
<th>Significance (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>174</td>
<td>64</td>
<td>0</td>
<td>0.003</td>
</tr>
<tr>
<td>Testosterone levels (nmol/l)</td>
<td>7.8 (1.9)</td>
<td>6.8 (2.3)</td>
<td>0</td>
<td>0.16</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60.9 (11.8)</td>
<td>58.5 (s.d.)</td>
<td>0</td>
<td>0.14</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>100.8 (21.8)</td>
<td>105.4 (20.1)</td>
<td>30 (12.9)</td>
<td>0.99</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>174.3 (7.2)</td>
<td>174.5 (5.5)</td>
<td>29 (12.5%)</td>
<td>0.31</td>
</tr>
<tr>
<td>BMI</td>
<td>33.3 (6.3)</td>
<td>34.3 (5.5)</td>
<td>37 (15.9%)</td>
<td>0.31</td>
</tr>
<tr>
<td>HbA1c</td>
<td>7.4 (1.3)</td>
<td>7.7 (1.3)</td>
<td>4 (1.7%)</td>
<td>0.21</td>
</tr>
<tr>
<td>Statin therapy</td>
<td>67 (54.4%)</td>
<td>33 (56%)</td>
<td>18 (7.6%)</td>
<td>0.88</td>
</tr>
<tr>
<td>ACE/ARB therapy</td>
<td>89 (54.6%)</td>
<td>36 (59%)</td>
<td>14 (5.9%)</td>
<td>0.65</td>
</tr>
<tr>
<td>Current smokers</td>
<td>27 (16.8%)</td>
<td>10 (17.2%)</td>
<td>17 (7.3%)</td>
<td>0.39</td>
</tr>
<tr>
<td>Pre-existing CVD</td>
<td>71 (44.3%)</td>
<td>22 (36.7%)</td>
<td>19 (8%)</td>
<td>0.34</td>
</tr>
</tbody>
</table>

*Mean with s.d.; *number with percentage within the groups; *numbers with percentage of the total; *analysis by t-test; *by χ².
Figure 3 Multivariate-adjusted survival curves using Cox regression model for treated and untreated groups compared with those with normal testosterone. The lighter broken line represents male subjects with total testosterone (TT) levels < 10.4 nmol/l without treatment, the continuous line represent those with TT levels > 10.4 nmol/l and the darker broken line represent those with TT levels < 10.4 nmol/l who received physiological testosterone replacement. HR, hazard ratio for decreased survival after adjusting for BMI, HbA1c, pre-existing cardiovascular disease, smoking, statin and ACEI/ARB therapy. *The number of patients alive at the start of the study and at the end of the study.

men with hypogonadism. The data showed that the survival curve followed a similar course to that of the normal testosterone group, whereas the untreated group had a worse prognosis. It is important to note that all patients treated with testosterone had careful adjustment of testosterone to achieve levels within the mid to upper normal range for healthy men. This is the first time any study on men with type 2 diabetes has shown that TRT may improve long-term survival outcome. This is especially important in men with type 2 diabetes who have a considerably reduced life expectancy.

A recently reported study involving 1031 male veterans over the age of 40 years showed that in men with low testosterone levels, TRT was associated with a decrease in mortality as compared with those who were not treated (27). This study compared survival in treated vs untreated men with hypogonadism with a mortality of 10.3% in the treated group and 20.7% in the untreated group. We found a similar rate of mortality in our study with 9.1% in the treated group compared with 20.1% in those who were not treated. Our study differed from that of veterans, in which we had the advantage of a control group of testosterone-replete men albeit with type 2 diabetes. In addition, our study included only men with type 2 diabetes, whereas the veterans study was a general population with either none or mixed co-morbidities (38% diabetes, 36% sexual dysfunction and 21 coronary heart disease). Nevertheless there are now two studies which are in general agreement that TRT improves survival in hypogonadal men.

It is appreciated that a limitation of this study in regard to the effect of TRT is that the data were collected retrospectively and that the patients were not randomised for treatment. In addition, those patients treated were clinically more overtly hypogonadal with symptoms and lower testosterone levels (mean baseline testosterone untreated, 7.8 ± 1.9 vs 6.8 ± 2.3 nmol/l treated; \( P = 0.003 \)) resulting in a treatment bias. However, the fact that the HR for mortality deteriorates when the treated patients (which include those with lower testosterone) are excluded suggests that this is not the case. We appreciate that it is important to recognise that these findings do need to be confirmed in an appropriately designed prospective placebo-controlled trial. However, the findings presented here are the first to suggest a favourable outcome of TRT specifically on survival in hypogonadal men with type 2 diabetes.

There were two groups of patients in the cohort: one screened for hypogonadism as part of research and the rest were identified from hospital laboratory records (all subjects had been assessed in our diabetes clinic) and the case notes were used to obtain the baseline data at the time of screening. The cause of death from hospital records and the national registry may not always reflect the exact cause of death. However, a large cohort makes this less likely to be a confounding factor. We did not find any significant difference between numbers of pre-existing CVD in the two groups, and deaths in the first 6 months were excluded from analysis. This is especially important because we have previously reported that low testosterone is a risk factor for mortality in men with proven coronary artery disease (5). The numbers of events in the whole groups were small and we are unable to predict the median survival in the Cox regression model.

Evidence is accumulating that a low testosterone is a risk factor for reduced survival particularly in relation to CVD. This evidence is supported by long-term follow-up studies in men treated for prostate cancer with androgen deprivation therapy (ADT) compared with those who were treated conservatively (28, 29). The majority but not all studies found an increase in CVD, myocardial infarction, incident diabetes, life-threatening arrhythmias and sudden cardiovascular death. Changes in key cardiovascular risk factors can be adversely affected within 3 months of initiation of ADT (29). A science advisory from the American Heart Association, American Cancer Society and the American Urological Association has recommended that all patients receiving ADT should have periodic follow-ups for the assessment of cardiovascular risk factors and those with coexisting CVD should have their treatment for secondary prevention optimised (29).
It is a common and generally accepted perception that low testosterone levels are a biomarker of ill health which occurs as a result of increased circulating cytokines in chronic diseases suppressing the hypothalamic–pituitary–gonadal axis. However, the role of testosterone deficiency in accelerating disease progression and equally that of replacing testosterone is not fully understood. As previously described, evidence suggests that testosterone deficiency promotes an increase in CIMT, a surrogate marker of in vivo atherosclerosis (14). Our study and the veterans study (27), both suggest that testosterone substitution in hypogonadal men improves mortality outcome.

TRT has been used to treat male hypogonadism since the late 1930s. Preparations of testosterone administration have improved over the last 15 years to allow testosterone replacement to within the normal physiological range. All patients in this study were treated by dose titration in the clinic to achieve serum levels in the mid to upper normal range. Several meta-analyses of trials of TRT have not found any increase in adverse cardiovascular events in hypogonadal men (30, 31, 32, 33). Furthermore, higher endogenous testosterone levels are not associated with cardiovascular events (33). One study which reported an increase in cardiovascular-related symptoms or events used twice the standard routine clinical initiation dose in frail elderly men with a high number of co-morbidities (34). A similar study using standard testosterone dose replacement did not report any increase in cardiovascular events (35). Testosterone replacement to normal testosterone levels has been used in a number of studies involving men with significant cardiac disorders including chronic stable angina and moderate chronic cardiac failure for up to 12 months with no evidence of adverse effects importantly including mortality (36, 37, 38, 39). The improvement in survival in this type 2 diabetes population supports the evidence that testosterone has a beneficial effect on health. However, it is recognised that until a long-term randomised placebo-controlled trial reports results, a definitive answer cannot be given.

In summary, this is the first study to demonstrate that low testosterone levels are associated with an increase in all-cause and cardiovascular mortality in men with type 2 diabetes. This study demonstrates that long-term testosterone replacement is not only safe in terms of mortality but may also improve survival in men with type 2 diabetes and hypogonadism. Further studies are needed to confirm these data. Our clinical practise is to replace testosterone to levels within the normal healthy range with careful monitoring of testosterone levels with adjustment of dose and safety (haematocrit, PSA) and this would appear to be a sensible and safe approach to clinical management. These findings are also in line with the beneficial effects of TRT on the cardiovascular risk factors in men with low testosterone that include insulin resistance, central obesity and cholesterol lowering and also suggest that these might be translated into long-term survival benefits (40).

Declaration of interest
V Muraleedharan was part supported by Bayer Healthcare UK. T H Jones has received research grants from Bayer Healthcare UK and received honoraria for advisory boards and educational lectures from Bayer Healthcare. Clarus, Lilly, Merck and Prostrakan. K S Channer has received honoraria for advisory boards and educational lectures from Bayer Healthcare and Prostrakan. H Marsh and D Kapoor have no conflicts.

Funding
V Muraleedharan is supported by Bayer Schering Pharma and funded by Barnsley Hospital NHSFT, Bayer Healthcare and Barnsley Hospital Endocrinology Research Fund.

Author contribution statement
V Muraleedharan researched the data and wrote the manuscript. D Kapoor contributed to research. H Marsh contributed to research and discussion. K S Channer contributed to research and review of manuscript. T H Jones conceived and designed the study, contributed to research, reviewed and edited the manuscript. T H Jones is the guarantor of this work and had full access to all of the data in the study and takes responsibility for the integrity of the data and accuracy of data analysis.

References


Received 16 April 2013
Revised version received 30 July 2013
Accepted 29 August 2013